Skip to main content

A metagenomic study of gut viral markers in amyloid-positive Alzheimer’s disease patients



Mounting evidence suggests the involvement of viruses in the development and treatment of Alzheimer’s disease (AD). However, there remains a significant research gap in metagenomic studies investigating the gut virome of AD patients, leaving gut viral dysbiosis in AD unexplored. This study aimed to fill this gap by conducting a metagenomics analysis of the gut virome in both amyloid-positive AD patients (Aβ + ADs) and healthy controls (HCs), with the objective of identifying viral signatures linked with AD.


Whole-genome sequence (WGS) data from 65 human participants, including 30 Aβ + ADs and 35 HCs, was obtained from the database NCBI SRA (Bio Project: PRJEB47976). The Metaphlan3 pipeline and linear discriminant analysis effect size (LEfSe) analysis were utilized for the bioinformatics process and the detection of viral signatures, respectively. In addition, the Benjamini–Hochberg method was applied with a significance cutoff of 0.05 to evaluate the false discovery rate for all biomarkers identified by LEfSe. The CombiROC model was employed to determine the discriminatory power of the viral signatures identified by LEfSe.


Compared to HCs, the gut virome profiles of Aβ + ADs showed lower alpha diversity, indicating a lower bacteriophage richness. The Siphoviridae family was decreased in Aβ + ADs. Significant decreases of Lactococcus phages were found in Aβ + ADs, including bIL285, Lactococcus phage bIL286, Lactococcus phage bIL309, and Lactococcus phage BK5 T, Lactococcus phage BM13, Lactococcus phage P335 sensu lato, Lactococcus phage phiLC3, Lactococcus phage r1t, Lactococcus phage Tuc2009, Lactococcus phage ul36, and Lactococcus virus bIL67. The predictive combined model of these viral signatures obtained an area under the curve of 0.958 when discriminating Aβ + ADs from HCs.


This is the first study to identify distinct viral signatures in the intestine that can be used to effectively distinguish individuals with AD from HCs.


Alzheimer’s disease (AD), which affects approximately 50 million people globally, is the leading cause of dementia and a serious global health concern [1]. The disease is characterized by the gradual accumulation of amyloid β-protein (Aβ) plaque and tangles of hyperphosphorylated tau neurofibrils, which result in neuroinflammation, neuronal loss, and cognitive impairment [2, 3]. Despite numerous hypotheses proposed to explain the pathogenesis and progression of AD, the precise causes of its onset and course remain unknown. Consequently, although several therapeutic approaches have been suggested, many clinical trials have failed to provide significant benefits [4, 5]. However, the Food and Drug Administration (FDA) recently approved lecanemab [6, 7] and aducanumab [8], which are monoclonal antibodies that target and remove beta-amyloid plaques in the brain. While these are positive developments, the need for effective AD treatments remains urgent. Researchers continue their quest to identify potential biomarkers for early disease detection so that treatment is initiated before the disease has progressed. However, the translation of these findings into clinical practice is still a long way off [9].

In recent years, there has been an explosion of interest in the gut microbiota-brain axis, which has been suggested as a therapeutic target for central nervous system illnesses [10]. A growing body of clinical and pre-clinical research points to the gut microbiome as a key player in the regulation of neurodegenerative processes, cognitive functions, and neurological disorders including AD [11,12,13]. Most studies rely on bacterial components of the gut microbiome rather than viral components. Furthermore, growing evidence supports the role of viruses in the etiology of AD, as well as the interaction between viral and bacterial components of the gut microbiome [14,15,16,17]. However, there is a lack of metagenomics research profiling the gut virome of AD patients, which could reveal unexplored gut viral “dark matter” in AD. The term human virome is used to describe the human microbiome’s viral components. The human virome, also called the viral metagenome, is the complete set of viruses found in humans. The virome comprised around 1013 particles per human and has a high level of heterogeneity. The human virome contains both eukaryotic and prokaryotic viruses including bacteriophages [18,19,20]. The effects of eukaryotic viruses on human health are wide-ranging, from those that cause very mild, self-limiting acute or chronic infections to those that have catastrophic outcomes [19, 21]. Bacteriophages, the most abundant member of the human virome, play an important role in the constant regulation of the diversity, richness, abundance, evolution, and physiology of microbial communities, so they may play an important role in human health by controlling bacteriome balance [22, 23]. Some examples of bacteriophage under research and potential therapy are Escherichia virus T4, which is well-studied and used in research that infects E. coli and shows potential for phage therapy [24]. PhiX174 phage is another bacteriophage that infects enteric bacteria like E. coli, serving as a valuable model organism in molecular biology research [25]. Pseudomonas phage targets and kill Pseudomonas bacteria, offering alternative treatment options for infections [26]. Bacteriophage ICP1 is a potential therapeutics against Vibrio-related infections like cholera [27]. These four bacteriophages demonstrate the diverse applications and potential benefits of potential phage therapy and molecular biology research. Continued research into bacteriophages may lead to innovative approaches for combating bacterial infections and maintaining a healthy bacteriome.

Bacteriome dysbiosis is believed to be an etiologic factor in the development of a number of diseases, including AD [13, 28]. Depending on the viral type, it is considered that viruses have a dual role in AD. Eukaryotic viruses have been discovered as probable causes of dementia, whereas some bacteriophages are potential therapeutic agents [29, 30]. Growing evidence links the Herpesviridae virus family, specifically HSV-1, to the etiology of AD. HSV-1 DNA has been detected within amyloid plaques located in the temporal and frontal cortices of individuals with AD. While several studies have indicated a higher prevalence of HSV-1 in AD patients, it is important to note that the exact pathogenic mechanisms remain unclear. It is believed that HSV-1 may not act as a sole causal agent in AD but rather its interactions with the host could contribute to the underlying pathophysiology of the disease [29, 31, 32]. Further research is needed to fully understand the intricate relationship between HSV-1 and the development of AD.

A previous study demonstrated the association of bacteriophages with improved executive function and verbal memory in flies, mice, and humans [30]. Through their research, the authors observed that individuals with elevated levels of Caudovirales and Siphoviridae in their gut virome exhibited enhanced executive function and verbal memory, as evidenced by both a discovery cohort (n = 114) and a validation cohort (n = 942). Conversely, heightened levels of Microviridae were linked to more severe impairments in executive functions. In an experiment involving mice, those receiving a virome transplant from humans with high levels of a specific Caudovirales (> 90% from the Siphoviridae family) performed better on a novel object recognition test, accompanied by increased expression of immediate early genes involved in memory formation in the prefrontal cortex. Additionally, the introduction of the 936 group of lactococcal Siphoviridae bacteriophages to the diet of Drosophila flies improved memory scores and upregulated memory-related brain genes. As a result, bacteriophages hold promise as potential actors within the virome-brain axis and warrant further investigation.

The current understanding of the connection between viruses and AD is supported by a substantial body of evidence [33,34,35]. However, there remains a notable research gap concerning the specific viral components present in the gut microbiome of AD patients. To address this knowledge deficiency, in the present study, we conducted a metagenomics analysis with the objective of identifying gut viral signatures that can effectively distinguish individuals with AD from healthy controls (HCs).

Methods and materials

Data collection

For our study, we utilized raw fecal sample data from the NCBI SRA database under the BioProject number PRJEB47976. This reference BioProject specifically focused on studying the gut bacteriome in two groups: Aβ + ADs (n = 75) and HCs (n = 100). The inclusion criteria for Aβ + ADs required them to meet the NIA-AA core clinical criteria for probable AD dementia, with a global clinical dementia rating (CDR) score ranging from 0.5 to 1.0. They also needed to exhibit evidence of cerebral amyloid β (Aβ) accumulation, as indicated by cerebrospinal fluid (CSF) levels of Aβ42 below 600 pg/ml. HCs were selected based on the absence of neurological or psychiatric disorders, no history of cognitive decline, and having a global CDR score of 0 and an MMSE score of 27 or higher. The objective of BioProject number PRJEB47976 was to explore the relationship between gut bacteriome signatures discriminating Aβ + ADs from HCs, where metagenomic sequencing analysis was used to assess the gut bacteriome, leading to the identification of 18 specific bacterial genera that showed significant associations with AD [36]. The combined contribution of these 18 genera was found to be linked to the presence and progression of AD, offering potential avenues for improvement. Since age and gender have been found to have a relevant effect on the gut microbiome [37,38,39], for our current study, we subsampled the reference study [36]. Initially, we selected 35 samples for each group. However, during the bioinformatics analysis, we had to exclude 5 samples due to their very low viral library sample size from the Aβ + AD group. This exclusion was crucial to ensure the reliability of the results, as low library size could potentially impact the accuracy of our findings, possibly resulting from improper DNA degradation or extraction for viral agents. In the end, we proceeded with a total of 65 samples, consisting of 30 individuals with Aβ + AD and 35 HCs. Despite the exclusion of 5 samples, our final subsampled cohort did not exhibit any statistically significant group differences in terms of age or gender.

In this study, a power analysis was conducted to determine the appropriate sample size for comparing two groups (Aβ + ADs and HCs) using Hedges’ g and Cohen’s d effect size measures. The significance level was set at 0.05 to control false positives, and a statistical power of 80% was aimed to detect true effects effectively. With a moderate effect size of 0.66, the calculated sample size of 30 Aβ + ADs and 35 HCs was considered sufficient to achieve the desired statistical power and detect meaningful differences between the groups. Differently from the reference study [36] that investigated the gut bacteriome, our specific focus in the current study was on investigating the gut viral signatures present in these samples, expanding the understanding of the gut virome in relation to AD. Supplementary Table S1 contains information about the selected samples including NCBI accession, age, gender, reads length (bp), and base pairs.

Bioinformatics and statistical analysis

Raw RNA-Seq data were quality-checked using FastQC v0.11.8 before being pre-processed with Cutadapt v2.8 to remove adapter sequences and low-quality bases. MetaPhlAn3 [40] was used to process the pre-processed sequencing reads, which rely on unique clade-specific marker genes identified from 17,000 reference genomes (13,500 bacterial and archaeal, 3500 viral, and 110 eukaryotic). The functions —ignore bacteria, —ignore eukaryotes, and —ignore archaea were used to exclude bacterial, eukaryotic, and archaeal taxa. The internal Metaphlan3 database was used to make taxonomic assignments. The feature count table was filtered to exclude counts < 2 with a minimum sample prevalence of 10%. The final feature count table for downstream analysis was generated using total sum of scales (TSS) normalization followed by rarefication for sample depth normalization.

Alpha diversity metrics such as observed, Shannon, Simpson, and differential viral communities (beta diversity) between Aβ + ADs and HCs were analyzed with the vegan package v2.5.6 in the R environment utilizing Bray–Curtis-based non-metric multidimensional scaling (NMDS) with the PERMANOVA significance test. Linear discriminant analysis effect size (LEfSe v1.1.01) ( (LDA > 2.00, and p < 0.05) was used to identify differentially abundant species between Aβ + ADs and HCs [41]. The area under the receiver operating characteristic (AUROC) analysis was used to determine the predictive value of each identified viral species, and the CombiROC tool [42] was used to select accurate viral feature combinations. MATLAB was used to visualize the final ROC curve.


Study design and participants

We analyzed a total of 65 samples from 30 Aβ + ADs and 35 HCs. In our subsampled cohort, there were no statistically significant group differences in age or gender among the participants, as we subsampled them based on these factors. Additionally, the reference study [36] reported no statistically significant differences between Aβ + AD and HCs in body mass index, arterial hypertension, diabetes mellitus, and rheumatoid arthritis status, while there were statistically significant differences in cognitive function (MMSE) with reduced performance in the Aβ + AD and higher usage of AChE inhibitors and antidepressants in Aβ + AD, as expected [36].

In our subsample, the total number of sequence reads obtained from 65 samples was 2,267,731,716, with a range of 26,776,840 to 46,799,316 and an average of 34,888,180. The total number of feature reads from all samples was 1,474,732, with an average of 22,688 OUT per sample and a range of 1124 to 421,766. Following 10% prevalence and 2 > filtration, eighty viruses were obtained and assigned to four phyla, seven families, twenty-two genera, and eighty species. All samples have Good’s coverage of more than 99%. At the phylum level, an interactive pie chart shows that Hofneiviricota, Pisuviricota, and Uroviricota were present in both groups, with Uroviricota being the most prevalent (Aβ + ADs: 78%, HCs: 87%). In Aβ + ADs, the abundance of Uroviricota is 9% lower than in HCs, while the abundance of Pisuvirico is 11% higher (Fig. 1A).

Fig. 1
figure 1

Gut virome composition profiles and core gut virome of Aβ + ADs and HCs. A, B Pie charts depicting the viral distribution in Aβ + AD individuals and HCs at the phylum and family levels, respectively. C, D Heatmaps of the core virome in Aβ + ADs and HCs at the genus and species levels, respectively

At the family level, an interactive pie chart reveals that Siphoviridae, Poxviridae, Myoviridae, and Podoviridae are the most abundant families in both groups. Comparing Aβ + ADs to HCs, the abundance of Siphoviridae and Podoviridae is reduced by 9% and 2%, respectively, whereas the abundance of Poxviridae is increased by 11% (Fig. 1B). Core virome at the genus and species levels was set for 20% prevalence of samples in each group and minimum 0.01% abundance. The core virome of the Aβ + ADs consisted of 9 genera and 19 species, whereas the core virome of HCs consisted of 19 and 29 viral features. The most prevalent genera in both groups were Siphoviridae unclassified, Epsilon15virus, Myoviridae unclassified, and Sk1viru. Betaenttomopoxvirus was only found in core virome of Aβ + ADs, whereas Hk97virus, Orthopoxvirus, Tl2011virus, and Nona33virus were found only in core virome of the HCs based on the setting scores (Fig. 1C). The heatmaps of the dominant core virome at the species level show that Enterobacteria phage BP 4795, Salmonella phage RE 2010, Choristoneura rosaceana entomopoxvirus, and Bacteroides phage B40 8 were only found in Aβ + ADs, whereas 14 species, including Lactococcus phage ul36, Lactococcus phage Tuc2009, Lactococcus phage bIL309, Lactococcus phage bIL286, Lactococcus phage bIL310, Escherichia virus P1, Escherichia virus HK022, Lactococcus phage BK5 T, Enterobacteria phage fiAA91 ss, Stx2 converting phage 86, Escherichia virus phiV10, Taterapox virus, Lactococcus phage phiLC3, and Escherichia phage P13374, were exclusive in core virome of HCs under conditions of 20% sample prevalence and > 0.01 abundance (Fig. 1D).

Virome richness and diversity in participants’ guts

Compared to HCs, Aβ + ADs exhibited lower alpha diversity in their gut virome profiles, as evidenced by the results of various diversity measures (observed index: p < 0.0001; Chao1 index: p < 0.0001; Shannon index: p = 0.0062; Simpson’s index: p = 0.0124) (Fig. 2A). Additionally, the analysis based on NMDS using Bray–Curtis dissimilarity distances and Jaccard index revealed notable interpersonal variations between Aβ + ADs and HCs (Bray–Curtis and PERMANOVA: p = 0.035; Jaccard index PERMANOVA: p = 0.033) (Fig. 2B).

Fig. 2
figure 2

Gut virome richness, diversity, and interpersonal variations in Aβ + ADs and HCs. A Boxplots displaying the alpha diversity measurements, including the observed and Chao1, Shannon, and Simpson’s indices between Aβ + ADs and HCs. B Beta diversity measurements based on NMDS using Bray–Curtis dissimilarity distances and the Jaccard index with PERMANOVA test assessment between Aβ + ADs and HCs

Taxonomic differences of gut virome in Aβ + ADs and HCs

LEfSe analysis was used to identify viral species that were differentially abundant between Aβ + ADs and HCs. Figure 3A shows that, based on LDA scores, compared to HCs, Aβ + ADs exhibited a significant increase in the abundance of Bacteroides phage B124 and a significant decrease in the abundance of several Lactococcus phages, including bIL285, Lactococcus phage bIL286, Lactococcus phage bIL309, Lactococcus phage BK5 T, Lactococcus phage BM13, Lactococcus phage P335 sensu lato, Lactococcus phage phiLC3, Lactococcus phage r1t, Lactococcus phage Tuc2009, Lactococcus phage ul36, and Lactococcus virus bIL67. Additionally, Aβ + ADs also exhibited reduced levels of Escherichia phage P13374 and Leuconostoc virus LN when compared to HCs. Pairwise Wilcoxon test for viral signatures between Aβ + ADs and HCs by LEfSe analysis (p < 0.05) is shown in (Fig. 3B).

Fig. 3
figure 3

Gut viral signatures significantly different between Aβ + ADs and HCs. A LEfSe analysis identified the most differentially abundant viral species in Aβ + ADs and HCs (p < .05; LDA score 2), viral species enriched in HCs are indicated with negative LDA scores (green), and viral species enriched in Aβ + ADs are indicated with positive LDA scores (red color). B Pairwise Wilcoxon test for each significant viral species identified by LEfSe analysis (p < 0.05) and Benjamini–Hochberg (BH) test, for false discovery rate (FDR) adjustment (q < 0.05)

We conducted the Benjamini–Hochberg (BH) test, a false discovery rate (FDR) controlling procedure, at a significance level of q < 0.05. As a result, Lactococcus phagebIL309, Escherichia phage P13374, Lactococcus phage bIL286, Lactococcus, and phage BK5 T achieved q values below 0.05, indicating significant findings. However, Lactococcus phage r1t, Enterococcus phage phiEf11, Lactococcus phage P335 sensu lato, Lactococcus phage phiLC3, Lactococcus phage Tuc2009, Leuconostoc virus LN04, and Lactococcus phage BM13 obtained q values ranging from 0.056 to 0.082, and the remaining four viral signatures obtained q values above 0.1, suggesting non-significant results when adjusting for multiple comparisons (Fig. 3B).

The ability power of the identified viral signatures to discriminate between individuals with Aβ + ADs and HCs was evaluated using AUROC analysis. This analysis aimed to assess the strength of these viral signatures as predictive classifiers for distinguishing between the two groups. The AUROC results indicated that viral signatures such as Lactococcus phage bIL309, Lactococcus phage bIL286, Lactococcus phage BK5 T, Lactococcus phage P335 sensu lato, and Bacteroides phage B124 14 provided a predictive value of 0.64 to 0.75 (AUROC; 95% CI, p < 0.05) whereas the remaining nine features exhibited AUROC values ranging from 0.60 to 0.64 with p-values ranging from 0.054 to 0.169 (AUROC; 95% CI) (Fig. 4A). Combining all fifteen statistically significant viral characteristics increased the AUROC score to 0.96% (p < 0.0001) (Fig. 4A).

Fig. 4
figure 4

Area under the receiver operating characteristic (AUROC) analysis of viral signatures for discriminating Aβ + ADs and HCs. A The area under the curve scores show the predictive values of the individual viral signature and the combined viral signatures. B Combined model graphical representation of viral signatures


This study investigated the composition of the gut virome in a cohort of Aβ + AD patients and HCs. The gut virome profiles of Aβ + ADs revealed reduced alpha diversity as compared to HCs, which suggested a lower bacteriophage richness. Our analyses showed that Uroviricota was the most frequent phylum of Caudovirales bacteriophages in both groups, and that was reduced by 9% in Aβ + ADs compared to HCs. The abundance of the family Siphoviridae was reduced by 9% in Aβ + ADs compared to HCs, whereas the abundance of the family Poxviridae was increased by 11%. A previous study discovered that Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans [30]. The study demonstrated that the levels of various Caudovirales, specifically the Siphoviridae family, were negatively correlated with the Trail Making Test (TMT) score, where a longer time taken to complete the test is generally associated with poorer performance or cognitive impairment, whereas the levels of Microviridae were positively correlated with the TMT score. Also, the same study discovered choline and glycine, the two most prominent sources of 1C units of folate, had the strongest relationships with Microviridae and Caudovirales levels [30]. Choline blocks the production of amyloid-beta plaques [43] and also choline supplementation reduces amyloidosis and increases choline acetyltransferase expression in the hippocampus of APPswePS1dE9 AD model mice [44]. A significant correlation exists between the degree of choline acetyltransferase activity loss in cerebral cholinergic neurons and the severity of dementia or cognitive deficits reported in AD [45]. Our LEfSe analysis revealed that Aβ + ADs significantly had a lower abundance of several Lactococcus phages including bIL285, Lactococcus phage bIL286, Lactococcus phage bIL309, Lactococcus phage BK5 T, Lactococcus phage BM13, Lactococcus phage P335 sensu lato, Lactococcus phage phiLC3, Lactococcus phage r1t, Lactococcus phage Tuc2009, Lactococcus phage ul36, and Lactococcus virus bIL67. Lactococcus phages belong to the order Caudovirales and have double-stranded DNA (dsDNA) genome. They are one of the most common phages that infect bacteria, particularly Lactococcus species [46]. Interaction between Lactococcus phage and Lactococcus bacterial species in AD should be examined, as bacteriophages regulate the diversity of Lactococcus bacteria and modulate their metabolic pathways. Lactococcus, a genus of lactic acid bacteria (LAB), is known for its production of lactic acid. Within humans, there exist two forms of lactic acid: l-lactic acid and d-lactic acid. While l-lactic acid is a commonly found compound in human metabolism, d-lactic acid is primarily produced by specific microorganism strains or less significant metabolic pathways. Despite their distinct structures, effects on the human body, and mechanisms of action, most studies do not differentiate between these two forms [47,48,49]. The production of lactic acid occurs through diverse metabolic pathways. l-lactic acid arises from the catabolism of amino acids and carbohydrates during glycolysis, whereas d-lactic acid is generated from the metabolism of carbohydrates, lipids, and intestinal bacteria. Both l-lactic acid and d-lactic acid impact neural network activity by binding to the hydroxycarboxylic acid receptor 1. l-lactic acid plays a crucial role in neural oxidative metabolism, contributing to memory formation, protein synthesis, synaptic remodeling, and axonal excitability. Conversely, d-lactic acid can hinder the uptake of l-lactic acid by neurons, resulting in inadequate neuronal energy metabolism and memory impairment [50,51,52,53].

Memory function relies on lactic acid [54, 55]. A previous study has shown that astrocytes in AD patients secrete less lactic acid, potentially contributing to the pathogenesis of the disease [56]. Neuronal energy metabolism depends on lactic acid produced by astrocytes [57, 58]. Lactic acid generated through glycolysis serves as an energy source for the brain and protects neurons from mitochondrial damage caused by Aβ protein accumulation [53]. Lactic acid appears to play a bidirectional role in AD etiology. On the one hand, long-term memory requires lactic acid from astrocytes to neurons. On the other hand, the accumulation of lactic acid in the brain stimulates Aβ protein deposition and excessive transmission of lactic acid into neurons, leading to lower pH, mitochondrial dysfunction, apoptosis, and impaired brain function [53,54,55]. Therefore, the regulation of gut bacteria and their lactic acid products by bacteriophage in AD requires further investigation. Our findings provide valuable insights into the role of gut dysbiosis in AD and align with a recent study that proposes a theoretical framework and hypothesis about the gut-brain axis and the role of gut microbiota in AD [59].

This study has several limitations that should be considered. The SRA database provided limited information on the clinical characteristics of the subjects, which restricted our ability to analyze associations between the gut virome and clinical features. We acknowledge the limitation of not having access to data on APOE genotype, diet, and medication use such as antibiotic and antidepressant use, which could influence gut virome diversity in our study. We recommend that further studies focus on exploring the impact of these variables on the gut virome to gain a more comprehensive understanding. Moreover, applying propensity scores on all these variables could offer an approach to match profiles between the two compared groups. Additionally, the sample size was relatively small. In future studies, maintaining a sufficient sample size above the required confidence level is imperative, particularly when planning further analysis post-study design. To prevent the exclusion of samples based solely on low viral library size, rigorous quality controls should be implemented during sample collection and RNA extraction. This approach will address the problem of low library size and reduce the need for further sample exclusions, ultimately enhancing the scientific robustness of studies. It is important to note that this study had a cross-sectional design, making it difficult to establish a cause-and-effect relationship between the gut virome. Additionally, cerebrospinal fluid biomarkers were not available for HCs, and thus, the present study recognizes a potential limitation of including AB + individuals in the HC group, some of whom might have altered microbiomes. Although this may have led our study to underestimate the differences between AB + ADs and HCs, the reported significant differences are valid and informative. To gain deeper insights, we recommend conducting longitudinal studies on individuals with preclinical AD and monitoring the changes in their gut microbiomes over time. Also, our cross-sectional study faces challenges in determining the causality between diet, gut dysbiosis, and AD. The impact of memory loss in individuals with AD may further hinder their ability to maintain a healthy diet leading to potential issues with forgetfulness related to eating their food. For more accurate insights, future research should prioritize longitudinal or caregiver-observed studies to mitigate these issues and better understand the complex interactions involved. We employed a combined model of AUROC analysis to assess the predictive power of all discriminatory biomarkers identified as a cohesive set. We acknowledge that the combined model may be influenced by preselected viral factors that were significant in distinguishing the groups initially. This could lead to higher AUROC values in that analysis and to ensure the generalizability of our finding, we recommend further validation in an independent (confirmatory) cohort in future studies. Another limitation is that the study did not measure metabolites in the collected gut samples and incorporating metabolomic analyses would provide a more comprehensive understanding of the gut virome’s role in AD. Additionally, simultaneous investigation of the bacteriome and virome, along with exploring their interactions, could offer valuable insights into the underlying mechanisms of AD pathogenesis.


In conclusion, this study suggests valuable new insights into the dysbiosis of the gut virome in Aβ + AD individuals compared to HCs. Through our metagenomic analyses, we have identified and characterized significant gut viral signatures that have the potential to serve as biomarkers for AD. These findings contribute to the understanding of the role of the gut virome in AD pathogenesis and may pave the way for the development of diagnostic or prognostic tools for AD based on the assessment of these viral signatures. Further research and validation studies are warranted to fully establish the clinical utility of these biomarkers in AD diagnosis and management.

Availability of data and materials

The metagenomic data are available under NCBI, SRA, Bio Project no. PRJEB47976. Permission based on free and unrestricted access to all of the data under Nucleotide Sequence Database Policies Science 298 [5597]: 1333 15 Nov 2002.



Alzheimer’s disease


Amyloid β-protein




Area under the receiver operating characteristic


Body mass index


Cerebrospinal fluid


Double-stranded DNA


Food and Drug Administration


Healthy controls


Herpes simplex virus 1


Linear discriminant analysis


Mini-Mental State Examination


National Center for Biotechnology Information


Non-metric multidimensional scaling


BioProject identifier


Sequence Read Archive


Trail Making Test


Whole Genome Sequencing


  1. Hodson R. Alzheimer’s disease. Nature. 2018;559(7715):S1–S1.

    Article  CAS  PubMed  Google Scholar 

  2. Bloom GS. Amyloid-β and Tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505.

    Article  PubMed  Google Scholar 

  3. Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study. J Neuroinflammation. 2020;17(1):151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Oxford AE, Stewart ES, Rohn TT. Clinical trials in Alzheimer’s disease: a hurdle in the path of remedy. Int J Alzheimer’s Dis. 2020;1(2020):1–13.

    Google Scholar 

  5. Rosenblum WI. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging. 2014;35(5):969–74.

    Article  CAS  PubMed  Google Scholar 

  6. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.

    Article  PubMed  Google Scholar 

  7. McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alz Res Therapy. 2022;14(1):191.

    Article  CAS  Google Scholar 

  8. Cummings J, et al. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410.

  9. Rasmussen J, Langerman H. Alzheimer’s disease – why we need early diagnosis. DNND. 2019;9:123–30.

    Article  Google Scholar 

  10. Varesi A, Pierella E, Romeo M, Piccini GB, Alfano C, Bjørklund G, et al. The potential role of gut microbiota in Alzheimer’s disease: from diagnosis to treatment. Nutrients. 2022;14(3):668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lin L, Zheng LJ, Zhang LJ. Neuroinflammation, gut microbiome, and Alzheimer’s disease. Mol Neurobiol. 2018;55(11):8243–50.

    Article  CAS  PubMed  Google Scholar 

  12. Cerovic M, Forloni G, Balducci C. Neuroinflammation and the gut microbiota: possible alternative therapeutic targets to counteract Alzheimer’s disease? Front Aging Neurosci. 2019;18(11):284.

    Article  Google Scholar 

  13. Bairamian D, Sha S, Rolhion N, Sokol H, Dorothée G, Lemere CA, et al. Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease. Mol Neurodegeneration. 2022;17(1):19.

    Article  CAS  Google Scholar 

  14. Sait A, Angeli C, Doig AJ, Day PJR. Viral involvement in Alzheimer’s disease. ACS Chem Neurosci. 2021;12(7):1049–60.

    Article  CAS  PubMed  Google Scholar 

  15. Lecuit M, Eloit M. The human virome: new tools and concepts. Trends Microbiol. 2013;21(10):510–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Li L, Mao S, Wang J, Ding X, Zen JY. Viral infection and neurological disorders—potential role of extracellular nucleotides in neuroinflammation. ExRNA. 2019;1(1):26.

    Article  Google Scholar 

  17. Neu U, Mainou BA. Virus interactions with bacteria: partners in the infectious dance. Evans MJ, editor. PLoS Pathog. 2020;16(2):e1008234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cobián Güemes AG, Youle M, Cantú VA, Felts B, Nulton J, Rohwer F. Viruses as winners in the game of life. Annu Rev Virol. 2016;3(1):197–214.

    Article  PubMed  Google Scholar 

  19. Liang G, Bushman FD. The human virome: assembly, composition and host interactions. Nat Rev Microbiol. 2021;19(8):514–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Garmaeva S, Sinha T, Kurilshikov A, Fu J, Wijmenga C, Zhernakova A. Studying the gut virome in the metagenomic era: challenges and perspectives. BMC Biol. 2019;17(1):84.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hulo C, Masson P, de Castro E, Auchincloss AH, Foulger R, Poux S, et al. The ins and outs of eukaryotic viruses: knowledge base and ontology of a viral infection. Alvisi G, editor. PLoS ONE. 2017;12(2):e0171746.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Naureen Z, Dautaj A, Anpilogov K, Camilleri G, Dhuli K, Tanzi B, et al. Bacteriophages presence in nature and their role in the natural selection of bacterial populations. Acta Bio Medica Atenei Parmensis. 2020;91(13-S):e2020024.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Papaianni M, Cuomo P, Fulgione A, Albanese D, Gallo M, Paris D, et al. Bacteriophages promote metabolic changes in bacteria biofilm. Microorganisms. 2020;8(4):480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Maghsoodi A, Chatterjee A, Andricioaei I, Perkins NC. How the phage T4 injection machinery works including energetics, forces, and dynamic pathway. Proc Natl Acad Sci USA. 2019;116(50):25097–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sillankorva S, Oliveira D, Moura A, Henriques M, Faustino A, Nicolau A, et al. Efficacy of a broad host range lytic bacteriophage against E. coli adhered to urothelium. Curr Microbiol. 2011;62(4):1128–32.

    Article  CAS  PubMed  Google Scholar 

  26. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. Goff SP, editor. J Virol. 2015;89(15):7449–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Boyd CM, Angermeyer A, Hays SG, Barth ZK, Patel KM, Seed KD. Bacteriophage ICP1: a persistent predator of Vibrio cholerae. Annu Rev Virol. 2021;8(1):285–304.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Chen C, Liao J, Xia Y, Liu X, Jones R, Haran J, et al. Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut. 2022;71(11):2233–52.

    Article  PubMed  Google Scholar 

  29. Murphy MJ, Fani L, Ikram MK, Ghanbari M, Ikram MA. Herpes simplex virus 1 and the risk of dementia: a population-based study. Sci Rep. 2021;11(1):8691.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodríguez M, Garre-Olmo J, Puig J, Ramos R, et al. Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans. Cell Host Microbe. 2022;30(3):340–356.e8.

    Article  CAS  PubMed  Google Scholar 

  31. Protto V, Marcocci ME, Miteva MT, Piacentini R, Li Puma DD, Grassi C, et al. Role of HSV-1 in Alzheimer’s disease pathogenesis: a challenge for novel preventive/therapeutic strategies. Curr Opin Pharmacol. 2022;63:102200.

    Article  CAS  PubMed  Google Scholar 

  32. Itzhaki RF. Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in Alzheimer’s disease (AD); underwhelming evidence against. Vaccines. 2021;9(6):679.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Miklossy J. Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med. 2011;13:e30.

    Article  PubMed  Google Scholar 

  34. Liu N, Jiang X, Li H. The viral hypothesis in Alzheimer’s disease: SARS-CoV-2 on the cusp. Front Aging Neurosci. 2023;15(15):1129640.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lee SE, Choi H, Shin N, Kong D, Kim NG, Kim HY, et al. Zika virus infection accelerates Alzheimer’s disease phenotypes in brain organoids. Cell Death Discov. 2022;8(1):153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Laske C, Müller S, Preische O, Ruschil V, Munk MHJ, Honold I, et al. Signature of Alzheimer’s disease in intestinal microbiome: results from the AlzBiom study. Front Neurosci. 2022;16:792996.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Bosco N, Noti M. The aging gut microbiome and its impact on host immunity. Genes Immun. 2021;22(5–6):289–303.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ghosh TS, Das M, Jeffery IB, O’Toole PW. Adjusting for age improves identification of gut microbiome alterations in multiple diseases. eLife. 2020;11(9):e50240.

    Article  Google Scholar 

  39. Kim N. Sex Difference of Gut Microbiota. In: Kim N, editor. Sex/gender-specific medicine in the gastrointestinal diseases [Internet]. Singapore: Springer Nature Singapore; 2022. p. 363–77. Cited 2023 Jun 18. Available from:

  40. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife. 2021;10:e65088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Sci Rep. 2017;7(1):45477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Velazquez R, Winslow W, Mifflin MA. Choline as a prevention for Alzheimer’s disease. Aging. 2020;12(3):2026–7.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Mellott TJ, Huleatt OM, Shade BN, Pender SM, Liu YB, Slack BE, et al. Perinatal choline supplementation reduces amyloidosis and increases choline acetyltransferase expression in the hippocampus of the APPswePS1dE9 Alzheimer’s disease model mice. Ohno M, editor. PLoS ONE. 2017;12(1):e0170450.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Fu AL, Li Q, Dong ZH, Huang SJ, Wang YX, Sun MJ. Alternative therapy of Alzheimer’s disease via supplementation with choline acetyltransferase. Neurosci Lett. 2004;368(3):258–62.

    Article  CAS  PubMed  Google Scholar 

  46. Deveau H, Labrie SJ, Chopin MC, Moineau S. Biodiversity and classification of lactococcal phages. Appl Environ Microbiol. 2006;72(6):4338–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Abedi E, Hashemi SMB. Lactic acid production – producing microorganisms and substrates sources-state of art. Heliyon. 2020;6(10):e04974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, et al. Correction: Lactate metabolism in human health and disease. Sig Transduct Target Ther. 2022;7(1):372.

    Article  Google Scholar 

  49. Pohanka M. D-Lactic acid as a metabolite: toxicology, diagnosis, and detection. Biomed Res Int. 2020;18(2020):1–9.

    Article  Google Scholar 

  50. Levitt MD, Levitt DG. Quantitative evaluation of D-lactate pathophysiology: new insights into the mechanisms involved and the many areas in need of further investigation. CEG. 2020;13:321–37.

    Article  CAS  Google Scholar 

  51. Brandt RB, Waters MG, Rispler MJ, Kline ES. D- and L-lactate catabolism to CO2 in rat tissues. Exp Biol Med. 1984;175(3):328–35.

    Article  CAS  Google Scholar 

  52. Tekkök SB, Brown AM, Westenbroek R, Pellerin L, Ransom BR. Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. J Neurosci Res. 2005;81(5):644–52.

    Article  PubMed  Google Scholar 

  53. Chen X, Zhang Y, Wang H, Liu L, Li W, Xie P. The regulatory effects of lactic acid on neuropsychiatric disorders. Discov Ment Health. 2022;2(1):8.

    Article  Google Scholar 

  54. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell. 2011;144(5):810–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Veloz Castillo MF, Magistretti PJ, Calì C. l-Lactate: food for thoughts, memory and behavior. Metabolites. 2021;11(8):548.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen Š, Gubert Olivé M, et al. PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer’s disease. Stem Cell Reports. 2017;9(6):1885–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Beard E, Lengacher S, Dias S, Magistretti PJ, Finsterwald C. Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol. 2022;11(12):825816.

    Article  Google Scholar 

  58. Yamagata K. Lactate supply from astrocytes to neurons and its role in ischemic stroke-induced neurodegeneration. Neuroscience. 2022;481:219–31.

    Article  CAS  PubMed  Google Scholar 

  59. Hung CC, Crowe-White KM, McDonough IM. A seed and soil model of gut dysbiosis in Alzheimer’s disease. Aging (Albany NY). 2023;15(12):5235–7.

    Article  PubMed  Google Scholar 

Download references


The author acknowledges the KIB Centre of the Karolinska Institute for contributing to the publication’s financing.


Open access funding provided by Karolinska Institute. This work was supported by the Karolinska Institute for publication funding, and SM is supported by Margaretha af Ugglas Stiftelse, King Gustav V:s and Queen Victorias Foundation, the regional agreement on medical training and clinical research [ALF] between Stockholm County Council and Karolinska Institutet, Gun och Bertil Stohnes Stiftelse, and Stiftelsen Gamla Tjänarinnor.

Author information

Authors and Affiliations



MGH designed the study, acquired and interpret the data, wrote the manuscript and conducted the analysis. SM interpreted the data, edited the first draft of the manuscript, critically reviewed, and approved the submitted version. DF critically reviewed and approved the submitted version.

Corresponding author

Correspondence to Mahin Ghorbani.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplemental Table S1.

Information about the selected samples.

Additional file 2: Supplemental Fig. S1.

Sequence sample size.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghorbani, M., Ferreira, D. & Maioli, S. A metagenomic study of gut viral markers in amyloid-positive Alzheimer’s disease patients. Alz Res Therapy 15, 141 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Gut virome
  • Alzheimer’s disease
  • Amyloid-β
  • Bacteriophage
  • Whole-genome sequencing